Stock Price & Analysis

Based on the provided data and current market context, here's my analysis of whether to buy or sell PFE stock:

Based on recent market data and analyst insights, Pfizer stock appears to be in a transitional phase with potential for long-term value. The company's revenue has stabilized after post-pandemic declines, with 14% operational growth excluding COVID-19 products. The current share price around $26 represents a significant value opportunity, trading at just 10x forward earnings.

SELL recommendation for short-term traders due to near-term headwinds, but BUY for long-term dividend investors seeking value. The company offers a robust 6.6% dividend yield that appears sustainable with a 60% payout ratio, while its oncology portfolio expansion through the Seagen acquisition positions it for potential growth in the 2030s.

Based on the provided data and market analysis, here is the price prediction for PFE stock in 2025:

Pfizer stock is expected to reach $32-35 by end of 2025, driven by its renewed growth in oncology segment and strategic acquisitions. The company's guidance of 10-18% earnings growth for 2025 and analysts' projected 14% annual growth over the next 3-5 years support this upward trajectory.

The key reasons behind this prediction:

1. Pfizer's specialty care products grew 11% YoY while oncology sales increased 25% YoY through first nine months of 2024, showing strong momentum in core business segments. The $43 billion Seagen acquisition is already contributing positively to oncology growth.

2. The company's 2025 revenue guidance of $61-64 billion, though flat compared to 2024, comes with projected adjusted EPS growth of 10-18% to $2.80-3.00 per share, indicating improving profitability despite revenue stabilization.

3. The stock currently trades at just 10x forward earnings with a 6.3% dividend yield, suggesting significant upside potential as earnings growth materializes and valuation multiples potentially expand.

The S1 support level for PFE Stock is $25.98 ,The R1 resistant level for PFE Stock is $26.9.

As of the end of day on 2025-01-24, the price of PFE Stock was $26.08.

The target price for PFE Stock according to analyst rating is 31.47, with the highest price target at 45.00 and the lowest at 25.00. Analysts have a Moderate Buy rating on PFE Stock overall.

The market cap of PFE is $147.9B.

Based on the provided data and recent market analysis, here's a comprehensive evaluation of PFE's valuation:

Current Market Position

Valuation Analysis

Key Findings:

1. PFE is currently trading at historically low levels, with a forward P/E of approximately 9x, significantly below the industry average of 12.58x. This suggests potential undervaluation from a pure multiple perspective.

2. The company's financial metrics show signs of stabilization after the post-COVID decline. Q3 2024 showed revenue of $17.7 billion, representing a 31.2% YoY increase, with a healthy gross profit margin of 72.48%.

3. The company maintains strong cash generation with $8.23 billion in free cash flow (FCF) over the TTM, supporting its recently increased dividend yield of over 6.5%.

4. Recent positive developments include promising results from the Phase 3 BREAKWATER trial, demonstrating PFE's continued R&D success.

5. Management's guidance for 2025 projects flat revenue ($61-64 billion) but expects 10-18% EPS growth, indicating improving operational efficiency.

Market Sentiment: The stock appears oversold based on current metrics, with multiple analysts suggesting the market has overreacted to the post-COVID revenue decline. The recent acquisition of Seagen and focus on oncology development present potential growth catalysts.

Conclusion: Based on the comprehensive analysis, PFE appears undervalued at current levels. The combination of:

• Strong cash flow generation
• Sustainable high dividend yield
• Pipeline developments
• Improving operational metrics Suggests the stock is trading below its intrinsic value.

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Based on the provided data and market research, here's a price prediction analysis for Pfizer (PFE) stock in 2030:

The stock is projected to reach approximately $45-50 per share by 2030, driven by Pfizer's strategic focus on oncology growth and multiple potential blockbuster drugs expected to launch by the early 2030s. The company's acquisition of Seagen and other biotech firms using pandemic-era profits positions it well for sustained revenue growth, with management anticipating 8 new blockbuster oncology drugs in its portfolio by the early 2030s.

The current depressed stock price of around $26 represents a significant undervaluation considering Pfizer's robust pipeline, 6.6% dividend yield, and projected 8% annual earnings growth through 2030. The company's pivot from COVID-19 products to a broader portfolio of treatments, particularly in oncology, should drive sustainable long-term value creation.

PFE has a total of 88000 employees.